Importantly, therapeutic disruption of the UBE2V1–HIF-1α axis markedly suppressed HCC tumorigenesis and metastasis in vivo, underscoring its potential as a target for novel therapeutic strategies in HCC. Here, UBE2V1 is linked to hepatocellular carcinoma.